💰 Dividend History

No dividend history available.

📅 Earnings & EPS History for AD

No earnings history available for this symbol.

📰 Related News & Research

• BOK Financial Corp Names Scott Andrews Head of Specialized Industries in March 2026 Press Release
  April 7, 2026
  

  Scott Andrews Appointed Head of Specialized Industries at BO...

• Neuronetics CFO Transition Announced; Company Reaffirms 2026 Financial Guidance and Focus on NeuroStar Advanced Therapy 1
  April 7, 2026
  

  Neuronetics Announces CFO Transition and Reaffirms 2026 Guid...

• Bel Fuse Announces New Business Unit Structure and Leadership Appointments to Drive Growth in Aerospace, Defense, Industrial Technology, and Data Solutions
  April 7, 2026
  

  Bel Fuse Inc. Announces Major Segment Realignment, Executive...

• Broadcom Signs Long-Term Deal With Google to Develop and Supply Custom TPUs and AI Hardware Through 2031, Expands Anthropic Partnership 5
  April 7, 2026
  

  Broadcom Inc. (AVGO) Files Form 8-K: Major Expansion of AI C...

• Where Food Comes From, Inc. Amends 2025 Annual Report to Address Material Weakness in Internal Controls
  April 7, 2026
  

  Where Food Comes From, Inc. Files Amendment to Annual Report...

• NorthStrive Defense Tech Secures Exclusive Option for Multi-Domain Drone Payload Technology for Air and Water Operations
  April 6, 2026
  

  NorthStrive Defense Tech Acquires Exclusive Option on Next-G...

• Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Expands Rare Disease Portfolio With FDA-Approved VYKAT XR for Prader-Willi Syndrome 1
  April 6, 2026
  

  Neurocrine Biosciences to Acquire Soleno Therapeutics: In-De...

• Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion, Expanding Rare Disease Portfolio with VYKAT XR for Prader-Willi Syndrome
  April 6, 2026
  

  Neurocrine to Acquire Soleno Therapeutics for \$2.9 Billion ...

• Strategy Inc (STRC) Reports 2026 Bitcoin Holdings, Financial Highlights, and Trading Information on NASDAQ
  April 6, 2026
  

  Strategy Inc. 8-K Report: Key Highlights for Investors (Apri...

• ImmunityBio Addresses FDA Concerns on Promotional Materials, Enhances Compliance Measures for ANKTIVA® 1
  April 6, 2026
  

  ImmunityBio Addresses FDA Concerns and Implements Enhanced A...

🔍 View more Reports